J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gonzalez, H. M.
Right arrow Articles by Hoyo-Vadillo, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonzalez, H. M.
Right arrow Articles by Hoyo-Vadillo, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

DRUG METABOLISM

CYP2C19- and CYP3A4-Dependent Omeprazole Metabolism in West Mexicans

Héctor M. Gonzalez, MSc, Elba M. Romero T, MSc, A. Aaron Peregrina L, MSc, Teresa de J. Chávez C, MSc, Estanislao Escobar-Islas, BSc, Felipe Lozano K, MD and Carlos Hoyo-Vadillo, PhD

From CUCEI, Universidad de Guadalajara, Mexico (Mr. Gonzalez, Ms. Romero T., Mr. Peregrina L., Ms. de J. Chávez C.); Division of Pharmacology, Cinvestav, IPN, Mexico (Mr. Escobar-Islas, Dr. Hoyo-Vadillo); and Hospital General de Zona #14, IMSS, Mexico (Dr. Lozano K.).

Omeprazole has been used as a drug probe for CYP2C19, but no systematic data are available for Mexican populations. The aim of this study was to evaluate the phenotype frequencies of the CYP2C19 polymorphism in West Mexicans. Besides omeprazole, sulfone was measured to evaluate CYP3A4 after administration of the 20-mg dose to 127 healthy volunteers. Logarithms of metabolic indexes of omeprazole/hydroxyomeprazole for CYP2C19 and omeprazole/omeprazole sulfone for CYP3A4 had trimodal distributions. Five subjects (4%) had a log CYP2C19 metabolic index below -0.9, suggesting an ultra-extensive phenotype. Poor metabolizers (log metabolic index > 0.6) were 6%. For CYP3A4, 11 subjects (9%) were below -0.3 of the log metabolic index. The log metabolic index of omeprazole/omeprazole sulfone was above the antimode of 0.6 for 11% of this population. The mean log metabolic index of CYP3A4 extensive metabolizers (80%) was 0.166, which seems to be higher than the data described for Caucasians and lower than that for Asians.


Key Words: OmeprazoleCYP2C19CYP3A4pharmacogeneticsMexicansgenetic polymorphisms

Address for reprints: Dr. Carlos Hoyo-Vadillo, Division of Pharmacology, Cinvestav, IPN, Av IPN 2508, 07360 Mexico DF, Mexico.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
PsychosomaticsHome page
J. de Leon, S. C. Armstrong, and K. L. Cozza
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
Psychosomatics, January 1, 2006; 47(1): 75 - 85.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
M. Gupta, A. Kovar, and B. Meibohm
The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction
J. Clin. Pharmacol., September 1, 2005; 45(9): 987 - 1003.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Clinical Pharmacology